About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Right In Front of You | Main | Samuel Johnson Was Right »

January 12, 2005

Our Friend the Nitrogen Atom

Email This Entry

Posted by Derek

My lab is starting work on another new project, which this time means another five-membered ring system that I haven't worked on before. I've done a lot of them, but this class I've missed out on somehow.

If you're going to do organic chemistry in a drug company, you'd better be on good terms with nitrogen atoms. I'd say that drugs with them outnumber drugs without by 10:1. The reasons aren't mysterious - amines can take up protons or donate them at just around the pHs that you find in living systems. And even the not-so-basic ones are still essential players. Nitrogen is a fine partner for hydrogen bonds, both donating and receiving, and those are the common currency of biomolecules, in my opinion.

So you'll be making plenty of amines and amides, and you'll be making plenty of the small-ring nitrogen compounds - imidazoles, oxazoles, pyrazoles and so on. My advice to grad students and post-docs is to learn some heterocyclic chemistry if you plan to interview in the drug industry, assuming we ever get around to hiring people again. (OK, don't panic - it's not that bad, not yet - but I fear that there's going to be a sadly reasonable supply of experienced candidates available this year.) Tell 'em that you know how to crank out the thiazoles and the oxadiazoles - it sure won't hurt, and it might just help.

As those of you outside chemistry may have suspected from all that gibberish, these systems have a systematic nomenclature. It gets a little tongue-twisty after a while, though, particularly if you're not being paid to say them (and make them.) I turned out a whole series of isoxazolidinones once, for example, a name that doesn't come trippingly off the tongue without a little preparation. Active compounds, you ask? You bet! So active that every one of them did something in mice, and what's more, every one did something different. But that, unfortunately, is not a feature that we value. So much for our "commitment to diversity", eh?

Comments (0) + TrackBacks (0) | Category: Life in the Drug Labs



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry